ArticlePloS one2014
Predictive gene signatures: molecular markers distinguishing colon adenomatous polyp and carcinoma.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Aberrant methylation patterns in colorectal cancer: a meta-analysis.Oncotarget · 2017Pooled it
- Tumor suppressor SLC9A2 inhibits colorectal cancer metastasis and reverses immunotherapy resistance by suppressing angiogenesis.Journal of experimental & clinical cancer research : CR · 2025Article
- MS4A superfamily molecules in tumors, Alzheimer's and autoimmune diseases.Frontiers in immunology · 2024Review
- Usefulness of COL11A1 as a Prognostic Marker of Tumor Infiltration.Biomedicines · 2023Article
- A Reddish Nodule on the Scalp: A Quiz.Acta dermato-venereologica · 2023Article
- Peptidomic changes in human serous colorectal cancer patients.Journal of gastrointestinal oncology · 2023Article
- Mendelian randomization study of causal link from gut microbiota to colorectal cancer.BMC cancer · 2022Article
- Game-theoretic link relevance indexing on genome-wide expression dataset identifies putative salient genes with potential etiological and diapeutics role in colorectal cancer.Scientific reports · 2022Article
- Article
- Hsa-miR-186-3p suppresses colon cancer progression by inhibiting KRT18/MAPK signaling pathway.Cell cycle (Georgetown, Tex.) · 2022Article
- Update of the keratin gene family: evolution, tissue-specific expression patterns, and relevance to clinical disorders.Human genomics · 2022Article
- Identification of hub genes and pathways in bladder cancer using bioinformatics analysis.American journal of clinical and experimental urology · 2022Article
- LINC00337 promotes tumor angiogenesis in colorectal cancer by recruiting DNMT1, which suppresses the expression of CNN1.Cancer gene therapy · 2021Article
- Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer.The pharmacogenomics journal · 2021Article
- Plasma Membrane Localized GCaMP-MS4A12 by Orai1 Co-Expression Shows Thapsigargin- and CaMolecules and cells · 2021Article
- Comprehensive analysis of biomarkers for prostate cancer based on weighted gene co-expression network analysis.Medicine · 2020Article
- Weighted gene co-expression network analysis identified MYL9 and CNN1 are associated with recurrence in colorectal cancer.Journal of Cancer · 2020Article
- KRT18 is correlated with the malignant status and acts as an oncogene in colorectal cancer.Bioscience reports · 2019Article
- Primary Cutaneous Mucinous Carcinoma of the Abdomen.Annals of dermatology · 2019Article
- Differentially expressed genesOncology letters · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancers exhibit abnormal molecular signatures associated with disease initiation and progression. Molecular signatures could improve cancer screening, detection, drug development and selection of appropriate drug therapies for individual patients. Typically only very small amounts of tissue are available from patients for analysis and biopsy samples exhibit broad heterogeneity that cannot be captured using a single marker. This report details application of an in-house custom designed GenomeLab System multiplex gene expression assay, the hCellMarkerPlex, to assess predictive gene signatures of normal, adenomatous polyp and carcinoma colon tissue using archived tissue bank material. The hCellMarkerPlex incorporates twenty-one gene markers: epithelial (EZR, KRT18, NOX1, SLC9A2), proliferation (PCNA, CCND1, MS4A12), differentiation (B4GANLT2, CDX1, CDX2), apoptotic (CASP3, NOX1, NTN1), fibroblast (FSP1, COL1A1), structural (ACTG2, CNN1, DES), gene transcription (HDAC1), stem cell (LGR5), endothelial (VWF) and mucin production (MUC2). Gene signatures distinguished normal, adenomatous polyp and carcinoma. Individual gene targets significantly contributing to molecular tissue types, classifier genes, were further characterised using real-time PCR, in-situ hybridisation and immunohistochemistry revealing aberrant epithelial expression of MS4A12, LGR5 CDX2, NOX1 and SLC9A2 prior to development of carcinoma. Identified gene signatures identify aberrant epithelial expression of genes prior to cancer development using in-house custom designed gene expression multiplex assays. This approach may be used to assist in objective classification of disease initiation, staging, progression and therapeutic responses using biopsy material.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.